Palabras claves: Angiotensin‐converting enzyme inhibitors (ACEi), antiviral, Biomolecules, Coronavirus disease of 2019 (COVID‐19), Medicinal Plants, Middle east respiratory syndrome (MERS), Renin–angiotensin–aldosterone system (RAAS), Severe acute respiratory syndrome coronavirus (SARS‐CoV), Viral entry inhibitors
Autores: Andrea Pino-Acosta, Fabián León-Tamariz, Jaime Alberto Naranjo-Morán, Jeffrey Vargas-Pérez, Juan Manuel Cevallos-Cevallos, Patricia Manzano Santana, Pieters L., Susana Alexandra Llivisaca Contreras, Vanden Berghe W.